Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz, a clinical psychologist, led the development of the ORR as a postdoctoral research fellow at Johns Hopkins University. About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”. Investor Contact: Robert Schatz.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

The Joint Blog

APRIL 17, 2020

But as an older user-base with more complicated medical conditions continue to grow, it is important to understand how THC could adversely impact other co-administered medications. Medical cannabis is typically prescribed for patients with severe conditions including inflammatory conditions (e.g.,

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

JULY 29, 2021

Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. Forward-looking statements. Some statements in this release may contain forward-looking information.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 9, 2021

The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has over $19 billion of assets under management and 95 ETFs listed on major Canadian stock exchanges.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Project CBD

MAY 3, 2023

CannMed: For what conditions do you think CBG has the most promise? It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research. Psoriasis is a well-known condition where people get not only joint pain but they also get these thick red patches and scales on their skin.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. Condensed Balance Sheet Data. . . The founding co-chairs are Andrew Monte, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JUNE 7, 2021

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Science also announced a new CTO, Sheldon Borkin , PhD, who joined in September 2021.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JANUARY 3, 2022

“Additionally, we are pleased with the guidance provided by the FDA regarding ANEB-001’s clinical and regulatory path in the U.S. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 26, 2021

With the anticipated launch of Pfizer’s oral COVID-19 antiviral drug candidate, Can-Fite has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials. dollars in thousands (except for share and per share data). . . Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JANUARY 6, 2022

He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. Anderson will be responsible for Anebulo’s global investor relations and public relations programs. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

NOVEMBER 12, 2021

In the event that the Maximum LTV is exceeded, Brown Shipley can make a call on the Guarantors requiring them to place cash with Brown Shipley for the aggregate amount of the excess exposure over the Maximum LTV. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. 1 Data published by Research and Markets, March 2018. Dr. Chapman Bio. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 9, 2022

These are the very first draft rules that we’re seeing, so it really is a kind of pivotal event.”. But this is the first time Oregonians have been allowed to see some of the nuts and bolts of what some predict could grow into a billion-dollar industry nationally, according to Data Bridge Market Research.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. a heart attack).

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

Cannabis Law Report

NOVEMBER 15, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. Investor Contact: Sanjay M.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. As a Contract Research Organization specialized in medical cannabis, Santé Cannabis offers consultation, data management and clinical trial services to a diverse range of clients from pharmaceutical, biotech and cannabis industries. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

MARCH 29, 2020

At an HIV Community Cannabis Education event held in Toronto, a cannabis company proudly declared their company had not had a single product recall to date. triggering new innovations and improved data quality through better user experiences. Product Quality in Manufacturing.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52